A Form 4 filed on September 10, 2026 discloses that Lorence H. Kim, a director at Revolution Medicines, Inc. (NASDAQ:RVMD), sold a total of 14,090 shares of common stock on September 8, 2026 through the Lorence Kim Revocable Trust under a Rule 10b5-1 trading plan.

Key Highlights

  • Total shares sold: 14,090 shares of common stock were disposed of across seven separate transactions on September 8, 2026.
  • Price range: Sales were executed at weighted average prices ranging from $206.6049 to $212.2693 per share, with individual trade prices spanning $206.47 to $212.3903 across all tranches.
  • Selling vehicle: All transactions were made by the Lorence Kim Revocable Trust, which held shares indirectly on behalf of the reporting person.
  • 10b5-1 plan: The sales were made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
  • Remaining beneficial ownership: Following all reported sales, the Trust holds 0 shares indirectly; the filing also notes 1,191 restricted stock units included in a prior balance.

Director Kim's Trust Completes Seven-Tranche Sale of Revolution Medicines Stock

According to the filing, Lorence H. Kim, identified as a director of Revolution Medicines, Inc., disposed of common stock through seven separate sale transactions, all dated September 8, 2026. Each transaction was coded "S" (sale) and executed through the Lorence Kim Revocable Trust. The filing states that all sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Trust on June 1, 2026.

The seven tranches involved the following share counts and weighted average prices, as reported: 706 shares at $206.6049, 999 shares at $207.3321, 3,587 shares at $208.5534, 2,853 shares at $209.56, 4,730 shares at $210.5028, 3,844 shares at $211.3588, and 371 shares at $212.2693. The filing notes that each tranche was executed across multiple individual trades, and the prices listed reflect weighted averages. The reporting person undertook to provide full information on individual trade prices within each range upon request to the SEC staff, the issuer, or a security holder.

Prior to the reported transactions, the filing indicates the Trust held 16,384 shares indirectly (after accounting for 1,191 restricted stock units noted in footnote 1). Following the completion of all seven sales, the Trust's indirect beneficial ownership in common stock stood at 0 shares, according to the filing. The form was signed by Jack Anders as attorney-in-fact for Lorence H. Kim on September 10, 2026.

What Was Disclosed

The filing reports that director Lorence H. Kim, through the Lorence Kim Revocable Trust, sold 14,090 shares of Revolution Medicines common stock on September 8, 2026 across seven price tranches under a pre-established Rule 10b5-1 plan, reducing the Trust's indirect holdings to zero.